Tag Archives: XBI

Top 5 Warren Buffett Stocks For 2019

&l;p&g;&l;img class=&q;dam-image getty size-large wp-image-688022858&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/688022858/960×0.jpg?fit=scale&q; data-height=&q;642&q; data-width=&q;960&q;&g; Portrait of male CEO in big corner office, looking out of window, at sunset. Photo Credit: Getty Royalty Free

&l;/p&g;&l;blockquote&g;&l;em&g;&a;ldquo;The heads of many companies are not skilled in capital allocation. Their inadequacy is not surprising because most bosses rise to the top because they have excelled in an area such as marketing, production, engineering, administration or, sometimes, institutional politics.&a;rdquo;&l;/em&g;&l;/blockquote&g;

-Warren Buffett, &l;a href=&q;http://www.berkshirehathaway.com/letters/1987.html&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q; target=&q;_blank&q;&g;1987 letter to Berkshire Hathaway shareholders&l;/a&g;

The Oracle of Omaha observed the lack of emphasis on capital allocation over 30 years ago, and since then, it seems that little changed. A 2015 Harvard Business Review article entitled &a;ldquo;&l;a href=&q;https://hbr.org/2015/04/ceos-dont-care-enough-about-capital-allocation&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q; target=&q;_blank&q;&g;CEO&a;rsquo;s Don&a;rsquo;t Care Enough About Capital Allocation&l;/a&g;&a;rdquo; found that hardly any top CEO&a;rsquo;s talked about return on invested capital (&l;a href=&q;https://www.newconstructs.com/education-return-on-invested-capital/&q; target=&q;_blank&q; rel=&q;noopener noreferrer&q; target=&q;_blank&q;&g;ROIC&l;/a&g;).

Top 5 Warren Buffett Stocks For 2019: Plexus Corp.(PLXS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Plexus Corp. (NASDAQ:PLXS) has been given an average recommendation of “Hold” by the nine brokerages that are currently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $60.75.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Plexus (PLXS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Plexus Corp. (NASDAQ:PLXS) CAO Angelo Michael Ninivaggi, Jr. sold 6,250 shares of Plexus stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $61.79, for a total value of $386,187.50. Following the completion of the transaction, the chief accounting officer now owns 28,402 shares of the company’s stock, valued at $1,754,959.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Top 5 Warren Buffett Stocks For 2019: SPDR S&P Biotech ETF (XBI)

Advisors’ Opinion:

  • [By Jim Crumly]

    Biotech shares jumped following news of some big deals, with the SPDR S&P Biotech ETF (NYSEMKT:XBI) soaring 4.4%. Gold stocks slumped; the VanEck Vectors Gold Miners ETF (NYSEMKT:GDX) fell 1.3%. 

  • [By Shane Hupp]

    Boyer & Corporon Wealth Management LLC decreased its holdings in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 9.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 64,434 shares of the exchange traded fund’s stock after selling 6,901 shares during the quarter. SPDR S&P Biotech ETF accounts for about 2.7% of Boyer & Corporon Wealth Management LLC’s investment portfolio, making the stock its 5th largest position. Boyer & Corporon Wealth Management LLC owned approximately 0.11% of SPDR S&P Biotech ETF worth $6,133,000 as of its most recent filing with the SEC.

  • [By Jim Crumly]

    Biotech stocks made gains today, with the SPDR S&P Biotech ETF (NYSEMKT:XBI) rising 1.3%. Consumer stocks were the laggards; the Consumer Staples Select Sector SPDR ETF (NYSEMKT:XLP) fell 0.6%.

Top 5 Warren Buffett Stocks For 2019: Lawson Products Inc.(LAWS)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Lawson Products (NASDAQ:LAWS) is scheduled to announce its earnings results on Thursday, April 19th. Analysts expect the company to announce earnings of $0.16 per share for the quarter.

Top 5 Warren Buffett Stocks For 2019: Guggenheim S&P Global Water ETF (CGW)

Advisors’ Opinion:

  • [By Logan Wallace]

    Jane Street Group LLC bought a new stake in shares of Invesco S&P Global Water Index ETF (NYSEARCA:CGW) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 209,583 shares of the company’s stock, valued at approximately $7,019,000.

Top 5 Warren Buffett Stocks For 2019: Galapagos NV(GLPG)

Advisors’ Opinion:

  • [By Keith Speights]

    Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) were trading 14% higher as of 11 a.m. EDT on Friday. The nice jump for the biotech stock came after Galapagos N.V. (NASDAQ:GLPG) announced disappointing results Thursday evening from a phase 2 clinical study evaluating C2 corrector GLPG2737 in treating cystic fibrosis (CF).

  • [By Cory Renauer]

    Galapagos NV (NASDAQ:GLPG) fell out of favor with a lot of investors after AbbVie (NYSE:ABBV) walked away from an important collaboration three years ago. Now that it looks like the discarded candidate could climb to the top of its class, though; the stock is more popular than ever.

  • [By Keith Speights]

    Gilead Sciences (NASDAQ:GILD) delivered some good news for its investors on Tuesday. The big biotech, along with its smaller partner, Galapagos (NASDAQ:GLPG), announced positive results from a phase 3 clinical study evaluating filgotinib in treating rheumatoid arthritis. Gilead’s share price got a nice bump from the news, while Galapagos stock skyrocketed.

Hot Blue Chip Stocks To Buy Right Now

General Electric was blasted on Wednesday by workers, retirees and shareholders bemoaning the downfall of the company they love.

At its annual meeting, GE (GE) got an earful from employees and investors who pleaded with management to right the ship after a disastrous year.

“I believe it was arrogance and a series of bad business decisions,” former employee Bill Freeda said. “Our board of directors clearly has been AWOL.”

Another shareholder said: “GE, which was once one of the preeminent companies in the world the bluest of blue chips is now an embarrassment.”

The past 12 months has been one of the darkest periods in GE’s 126-year history. A cash crisis, brought on by years of bad deal-making, forced GE to cut its dividend in half and lay off thousands of workers. GE’s stock price has crashed by 50%, and calls to kick it out of the Dow have grown louder.

Despite the deep criticism of past and current GE leaders, the company’s nominees to the board were all elected on Wednesday. None of the shareholder proposals calling for reform were adopted, though one pushing for splitting the CEO and chairman roles received strong support.

Hot Blue Chip Stocks To Buy Right Now: Maxwell Technologies, Inc.(MXWL)

Advisors’ Opinion:

  • [By Logan Wallace]

    Maxwell Technologies (NASDAQ: MXWL) and Arotech (NASDAQ:ARTX) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, valuation and risk.

  • [By Logan Wallace]

    Shares of Maxwell Technologies Inc. (NASDAQ:MXWL) have earned an average recommendation of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $7.25.

  • [By Logan Wallace]

    News articles about Maxwell Technologies (NASDAQ:MXWL) have been trending somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Maxwell Technologies earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave press coverage about the electronics maker an impact score of 46.3845155482228 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

  • [By Ethan Ryder]

    HRG Group (NYSE: HRG) and Maxwell Technologies (NASDAQ:MXWL) are both consumer staples companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, valuation and dividends.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Maxwell Technologies (MXWL)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Blue Chip Stocks To Buy Right Now: Nuveen AMT-Free Municipal Income Fund(NEA)

Advisors’ Opinion:

  • [By Stephan Byrd]

    BB&T Securities LLC cut its holdings in Nuveen Amt-Free Quality Municpl Incm Fnd (NYSE:NEA) by 3.7% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 260,949 shares of the company’s stock after selling 10,037 shares during the quarter. BB&T Securities LLC owned about 0.10% of Nuveen Amt-Free Quality Municpl Incm Fnd worth $3,392,000 at the end of the most recent quarter.

  • [By Joseph Griffin]

    Wells Fargo & Company MN raised its holdings in Nuveen AMT-Free Municipal (NYSE:NEA) by 8.7% during the first quarter, HoldingsChannel reports. The institutional investor owned 4,674,452 shares of the company’s stock after buying an additional 372,370 shares during the period. Wells Fargo & Company MN’s holdings in Nuveen AMT-Free Municipal were worth $60,768,000 as of its most recent SEC filing.

Hot Blue Chip Stocks To Buy Right Now: SPDR S&P Biotech ETF (XBI)

Advisors’ Opinion:

  • [By ]

    Fast forward 12 months and the SPDR S&P Biotech ETF (NYSE:XBI) is higher by almost 50%. But this rally aint over yet. The beginning of 2018 trading is already flashing a new biotech breakout a move that could cement these stocks as some of the years most explosive market leaders.

  • [By ]

    Remember the SPDR S&P Biotech ETF (NYSE:XBI) chart I showed you Friday? Take a look at this ETF bouncing off its 50-day moving average one more time:

  • [By Money Morning News Team]

    But the biotech sector crushed the market, with the SPDR S&P Biotech ETF (NYSE: XBI) returning a market-beating 43.36% in 2017, nearly double the broader S&P 500.

Top 10 Blue Chip Stocks To Invest In Right Now

The stock market gave up ground on Tuesday, but investors saw major benchmarks recover from their worst levels of the day to finish down less than half a percent. Early in the day, poor earnings results from blue chip components of the Dow Jones Industrials weighed on market sentiment, and ongoing uncertainty about whether the Trump administration will be able to deliver on promised government reforms made some investors feel less confident about the future. However, several companies reported good news despite the dour mood on Wall Street, and GNC Holdings (NYSE:GNC), Stratasys (NASDAQ:SSYS), and Cabela’s (NYSE:CAB) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.

GNC eases shareholders’ concerns

Shares of GNC Holdings jumped 24% after the company posted first-quarter results that, while not perfect, were still not as bad as some investors had feared. Revenue fell 4% from year-ago levels, and same-store sales dropped 3.9% in company-owned locations and 4.6% in domestic franchise stores. Moreover, net income dropped by more than half, leaving the company with just $0.37 per share in adjusted earnings. Yet those numbers encouraged those who are patient enough to give GNC time to remake itself, and CEO Bob Moran pointed to the company’s One New GNC transformation strategy as having shown signs of early success. With new loyalty programs producing some positive effects on transaction counts and volume, GNC hopes that business metrics will hit bottom and start to grow again in the near future.

Top 10 Blue Chip Stocks To Invest In Right Now: iShares Core S&P Total US Stock Mkt (ITOT)

Advisors’ Opinion:

  • [By Todd Shriber, ETF Professor]

    Hundreds of exchange traded funds offer investors broad market exposure and many do so with nominal fees. Among the least expensive is the iShares Core S&P Total U.S. Stock Market ETF (NYSE: ITOT).

Top 10 Blue Chip Stocks To Invest In Right Now: Powell Industries Inc.(POWL)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Powell Industries, Inc. (NASDAQ: POWL) were down 14 percent to $40.06. Powell Industries reported Q4 adjusted earnings of $0.54 per share on sales of $129.8 million.

Top 10 Blue Chip Stocks To Invest In Right Now: Atlantic Power Corporation(AT)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Monday, utilities shares rose by just 0.1 percent. Meanwhile, top losers in the sector included Atlantic Power Corp (NYSE: AT), down 2 percent, and Pampa Energia S.A. (ADR) (NYSE: PAM), down 4 percent.

  • [By Lisa Levin]

    In trading on Tuesday, utilities shares slipped by 0.02 percent. Meanwhile, top losers in the sector included Companhia de Saneamento Basico (ADR) (NYSE: SBS), down 3 percent, and Atlantic Power Corp (NYSE: AT), down 3 percent.

  • [By Lisa Levin] Related WR Earnings Scheduled For February 24, 2016 Mid-Day Market Update: Ocata Therapeutics Climbs On Acquisition News; Textura Shares Slip
    Related AT Mid-Morning Market Update: Markets Open Higher; Tiffany Misses Q2 Expectations PVH Corp, Atlantic Power, Carlyle Group Lead Monday's After-Hours Movers Atlantic Power's (AT) CEO Jim Moore on Q4 2015 Results – Earnings Call Transcript (Seeking Alpha)

    Toward the end of trading Thursday, the Dow traded down 0.24 percent to 16,960.40 while the NASDAQ declined 0.38 percent to 4,656.49. The S&P also fell, dropping 0.17 percent to 1,985.91.

  • [By Lisa Levin]

    In trading on Tuesday, utilities shares rose by just 0.1 percent. Meanwhile, top losers in the sector included Atlantic Power Corp (NYSE: AT), down 2 percent, and SCANA Corporation (NYSE: SCG) down 1 percent.

Top 10 Blue Chip Stocks To Invest In Right Now: Dicerna Pharmaceuticals, Inc.(DRNA)

Advisors’ Opinion:

  • [By Monica Gerson]

    The list of below stocks is notable as the shares have traded on sequentially increasing volume spanning the trading days from September 16 to September 20:

  • [By Lisa Levin] Related CXW Trump Or Clinton: Who Would Create More Jobs? The 2016 Economics Nobel Prize Winner's Case Against Private Prisons: Contracts Are The Key Wall Street Breakfast: Trump Takes The White House (Seeking Alpha)
    Related SAEX 20 Biggest Mid-Day Losers For Friday 22 Stocks Moving In Friday's Pre-Market Session SAExploration wins $35M seismic data deal (Seeking Alpha)
    Gainers
    Corrections Corp Of America (NYSE: CXW) shares rose 16.3 percent to $16.50 in pre-market trading following Donald Trump's victory.
    SAExploration Holdings, Inc. (NASDAQ: SAEX) shares rose 15.4 percent to $7.26 in pre-market trading after the company reported a new $35 million deep water ocean-bottom marine project award.
    The GEO Group Inc (NYSE: GEO) shares rose 12.9 percent to $26.95 in pre-market trading following Donald Trump's victory.
    Cloud Peak Energy Inc. (NYSE: CLD) rose 12.3 percent to $7.40 in pre-market trading after gaining 0.30 percent on Tuesday.
    Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) rose 11.7 percent to $10.35 in pre-market trading. Ariad Pharmaceuticals disclosed that its Phase 1/2 trial data on investigational drug brigatinib were published in The Lancet Oncology.
    AK Steel Holding Corporation (NYSE: AKS) rose 11.2 percent to $6.75 in pre-market trading after gaining 3.23 percent on Tuesday.
    Pretium Resources Inc (NYSE: PVG) rose 11 percent to $10.50 in pre-market trading after declining 1.66 percent on Tuesday.
    First Majestic Silver Corp (NYSE: AG) rose 9.3 percent to $8.90 in the pre-market trading session. First Majestic reported Q3 earnings of $0.07 per share on revenue of $79.3 million. Silver futures gained 2.2 percent to $18.77 an ounce.
    Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) rose 9.2 percent to

Top 10 Blue Chip Stocks To Invest In Right Now: Yum! Brands, Inc.(YUM)

Advisors’ Opinion:

  • [By ]

    These figures should be a relief for Niccol, who joined the company from Yum! Brands’ (YUM) Taco Bell in February. While he was largely welcomed by investors and received industry affirmation, some critics were skeptical of his franchising background, operational savvy and the disparity in ethos between Chipotle and Taco Bell.

  • [By WWW.THESTREET.COM]

    As a tiebreaker, Cramer turned to Yum Brands (YUM) , where Pizza Hut also saw some softness, but was able to eek out an increase in gross margins.

    Pizza delivery is the ultimate stay-at-home economy play, Cramer said, but clearly the rising tide is not lifting all boats, and only Domino’s is able to buck the trend with its superior technology initiatives.

  • [By ]

    Nearly 10 months ago, Cramer told viewers to buy shares of Yum Brands (YUM) and sell its counterpart, Yum China Holdings  (YUMC) . Since that recommendation, shares of Yum are up 11%, while Yum China has fallen over 5%. What should investors do now? Cramer took a fresh look to find out.

  • [By Max Byerly]

    In other Yum! Brands news, CEO Brian R. Niccol sold 2,294 shares of Yum! Brands stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $84.90, for a total value of $194,760.60. Following the completion of the transaction, the chief executive officer now directly owns 10,160 shares of the company’s stock, valued at approximately $862,584. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Brian R. Niccol sold 945 shares of Yum! Brands stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $79.90, for a total value of $75,505.50. Following the completion of the transaction, the chief executive officer now directly owns 10,785 shares of the company’s stock, valued at $861,721.50. The disclosure for this sale can be found here. Insiders own 0.63% of the company’s stock.

    COPYRIGHT VIOLATION NOTICE: “Yum! Brands (YUM) Given News Sentiment Rating of 0.13” was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The legal version of this report can be read at www.tickerreport.com/banking-finance/3377799/yum-brands-yum-given-news-sentiment-rating-of-0-13.html.

    About Yum! Brands

  • [By ]

    For example, when Kentucky Fried Chicken changed its name to KFC (NYSE: YUM), it did so to get the word “fried” out of its advertising in an age of health-conscious customers. Cigarette maker Phillip Morris did the same when they rebranded to Altria (NYSE: MO) in 2003. The political pressures associated with “big tobacco” created a need for a less caustic moniker.

Top 10 Blue Chip Stocks To Invest In Right Now: SPDR S&P Biotech ETF (XBI)

Advisors’ Opinion:

  • [By ]

    The SPDR S&P Biotech ETF (NYSE:XBI) and the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) were each approaching important support levels back in mid-November.

  • [By ]

    And while the big drug companies will experience a significant adjustment, biotech companies, with their focus on long term results and outright cures in some cases, are probably poised to perform. The best way to get invested would be with the Biotech Spider ETF (NYSE: XBI).

  • [By ]

    More importantly, the SPDR S&P Biotech ETF (NYSE:XBI) has proven resilient during the volatility spike and selloff.

    In fact, XBI never closed significantly below its 50-day moving average as investors dumped stocks. That turned out to be a huge tell

  • [By Jim Crumly]

    Tech stocks were strong today, but biotech really took off on merger and acquisition news; theSPDR S&P Biotech ETF (NYSEMKT:XBI) jumped 2.7%.

  • [By ]

    The SPDR S&P Biotech ETF (NYSE:XBI) a good measure of small-cap biotech stocks gained almost 6% yesterday. Meanwhile, the large-cap iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) jumped almost 4%. The biotech buying frenzy helped lift the Nasdaq Composite to a gain of almost 1% in Mondays session.

Top 10 Blue Chip Stocks To Invest In Right Now: Kronos Worldwide Inc(KRO)

Advisors’ Opinion:

  • [By Monica Gerson]

    Kronos Worldwide, Inc. (NYSE: KRO) is projected to post a quarterly loss at $0.13 per share on revenue of $308.50 million.

    Energen Corporation (NYSE: EGN) is estimated to post a quarterly loss at $0.67 per share on revenue of $122.91 million.

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    Albemarle Corporation (NYSE: ALB): Free Stock Analysis Report
     
    Celanese Corporation (NYSE: CE): Free Stock Analysis Report
     
    Kronos Worldwide Inc (NYSE: KRO): Free Stock Analysis Report
     
    Koppers Holdings Inc. (NYSE: KOP): Free Stock Analysis Report
     
    Chemours Company (The) (CC): Free Stock Analysis Report
     
    Kraton Corporation (NYSE: KRA): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.
     
    Zacks Investment Research

  • [By Zacks]

    Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
     
    Kronos Worldwide Inc (NYSE: KRO): Free Stock Analysis Report
     
    Westlake Chemical Corporation (NYSE: WLK): Free Stock Analysis Report
     
    DAQO New Energy Corp. (NYSE: DQ): Free Stock Analysis Report
     
    Newmont Mining Corporation (NYSE: NEM): Free Stock Analysis Report
     
    To read this article on Zacks.com click here.
     
    Zacks Investment Research

Top 10 Blue Chip Stocks To Invest In Right Now: National Steel Corporation(SID)

Advisors’ Opinion:

  • [By Lisa Levin]

    Basic materials shares climbed by 1.52 percent in trading on Friday. Meanwhile, top gainers in the sector included Companhia Siderurgica Nacional (ADR) (NYSE: SID), and Core Molding Technologies, Inc. (NYSE: CMT).

Top 10 Blue Chip Stocks To Invest In Right Now: Alliance Data Systems Corporation(ADS)

Advisors’ Opinion:

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Thursday was Alliance Data Systems Corp. (NYSE: ADS) which jumped 8.3% to $260.56. The stocks 52-week range is $185.02 to $263.40. Volume was roughly 1.2 million which is above the daily average of around 606,000 shares.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Tuesday was Alliance Data Systems Corp. (NYSE: ADS) which traded down 3.9% at $238.00. The stocks 52-week range is $185.02 to $254.94. Volume was 1.6 million versus the daily average of 577,000 shares.

  • [By Ben Levisohn]

    Alliance Data Systems (ADS) soared to the top of the S&P 500 today after beating the Street’s earnings and revenue expectations.

    Getty Images

    Alliance Data Systemsgained 8.3% to $260.62, while the S&P 500 rose 0.8% to 2,355.84.

    Evercore ISI’s David Togut and team argue that Alliance Data Systems is “checking the right boxes.” They explain:

    ADS’ 1Q/17 earnings reinforced our conviction that net charge offs will stabilize at the end of this year, driving accelerating earnings growth in 2018. Card Services surpassed our revenue and EBITDA forecasts fueled by an 80 basis point increase in gross card yield thanks to rising interest rates. Epsilon’s revenue growth accelerated to 7% from a 1% decline in 4Q/16 driven by double digit growth in Automotive, Agency and digital CRM plus an easy comparison. LoyaltyOne revenue and EBITDA fell below our estimates given soft results from AIR MILES, which is adjusting its value proposition after the Ontario Legislature last December eliminated the expiration date on AIR MILES. Overall, ADS remains on track to generate double-digit adjusted EBITDA and EPS gains in 2017, and in 2018 to accelerate EPS growth to the mid-teens given slowing headwinds from delinquencies plus operating leverage from stabilizing net charge-off rates.

    Alliance Data Systems’ market capitalization rose to $14.6 billion today from $13.5 billion yesterday.

  • [By Teresa Rivas]

    Alliance Data Systems (ADS) was the worst performer in the S&P 500 Tuesday.

    Getty Images

    ADS shares fell $9.32, or 3.8%, to $238.32, compared to the S&P 500, which fell 3.38 points, or 0.14%, to 2353.78.

    The shares were hurt by a bearish note from Oppenheimer: Analysts Ben Chittenden and Dominick Gabriele initiated coverage of the stock with an Underperform rating and a $185 price target.

    Details from the note:

    Long investors seem generally to believe that the profitability of ADS’s capital-light/data-driven/tech-based businesses (Epsilon/LoyaltyOne) will turn relatively soon and that EPS will be driven by more than just the card business. The logical conclusion is the multiple should be FinTech-based. We think it’s just as easy to make the case that, while ADS had a first-mover advantage on data-driven, SKU-level analytics, competitive advantage is diminishing and the profitability of these businesses will likely take longer to turn (and likely not return to historical levels). Thus, earnings will continue to be driven by the balance sheet-intensive card business (our ’18E EPS is 6% below consensus) and should be valued as such, we think.

    Advanced Micro Devices(AMD) was the worst performer in the S&P 500 yesterday.

     

  • [By Garrett Baldwin]

    WTI crude oil prices added 1.2% to hit $69.31 per barrel, while Brent crude added 1.4% to hit $74.50. The uptick came after Saudi Arabia hinted that it would like to see oil prices hit the top end of the $80 to $100 range. The key oil supplier has been working with other OPEC producers and Russia to support crude prices to reduce excessive global production. The nations’ agreement is expected to extend well into 2019 and potentially beyond that time frame.
    This morning, as it topped earnings expectations, Procter & Gamble Co. (NYSE: PG) announced it will purchase the consumer health business of German pharma giant Merck KGaA (OTCMKTS: MKGAF) for nearly $4.2 billion. The deal will expand on P&G’s vitamins and health supplement business. This is the first deal made by P&G since activist investor Nelson Peltz won a board seat last year.
    Four Stocks to Watch Today: PM, AXP, AMZN, COST
    Shares of Phillip Morris International Inc.(NYSE: PM) dropped 3.6% in pre-market hours after the company fell short of revenue expectations. Despite reporting earnings per share (EPS) of $1.00, a figure that topped estimates by $0.12, the firm fell short of the $7.02 billion in revenue forecasted by analysts.
    American Express Co.(NYSE: AXP) popped nearly 4% after the company easily topped Wall Street earnings after the bell Wednesday. The firm’s strategy to spend $2.35 billion on customer rewards promotions wooed a large amount of accounts and upgrades during the first three months of 2018. AXP reported EPS of $1.86 on top of $9.72 billion in revenue. Wall Street forecasted $1.71 per share on $9.20 billion.
    Amazon.com Inc.(Nasdaq: AMZN) is in focus after two stunning revelations emerged from the company on Wednesday. CEO Jeff Bezos announced that the company has more subscribers to its Prime service than Costco Corp.(Nasdaq: COST), while the average Amazon employee earned under $30,000 in 2017.
    Look for additional earnings reports from Skechers USA In

Top 10 Blue Chip Stocks To Invest In Right Now: RenaissanceRe Holdings Ltd.(RNR)

Advisors’ Opinion:

  • [By Logan Wallace]

    RenaissanceRe (NYSE: RNR) is one of 73 publicly-traded companies in the “Fire, marine, & casualty insurance” industry, but how does it compare to its rivals? We will compare RenaissanceRe to similar companies based on the strength of its dividends, earnings, analyst recommendations, institutional ownership, valuation, risk and profitability.

  • [By WWW.MONEYSHOW.COM]

    RenaissanceRe Holdings (RNR) is a global provider of reinsurance, as well as various types of insurance and related services. The company was founded in 1993 and is headquartered in Bermuda, notes Jack Adamo, editor of Insiders Plus.

Rounds Report: Achaogen And Eleven To Clear Their Binaries For Substantial Gains

Were emphasizing the knowable by predicting how certain people and companies will swim against the current. Were not predicting the fluctuation in the current. – Charlie Munger

Trading Analytics

Welcome to this edition of Integrated BioSci Rounds Report for April 27, 2018. As usual, well elucidate notable trading analytics for the day, recent insider transactions, and interesting market developments. Without further ado, lets take an overall assessment of the bioscience space. As follows, the iShares of NASDAQ Biotechnology Index (NASDAQ:IBB) traded up $0.31 (+0.29%) at $105.61. Moreover, the SPDR S&P Biotech (NYSE:XBI) exchanged hands $0.58 higher at $88.42 (for +0.66% gains). Its likely that investors were trading with a more positive sentiment for the day. Regardless of the daily inclination, there are substantial prospects in the bioscience sector: one that delivers hope for patients while rewarding supporters with substantial wealth in the long haul.

Figure 1: Notable BioSci movers. (Source: Morningstar)

Moving to specific equities, Eleven Biotherapeutics (NASDAQ:EBIO) – a company focusing on the innovation and commercialization of the novel molecules, Targeted Protein Therapeutics (TPTs) – won the highlight for the day. Following a strong momentum this week, the shares exchanged hands $0.16 higher to close the session at $2.51 (for over 6.8% profits). In addition, the stock added over 31% and 130% for the past week and previous month, respectively.

Of note, TPT is a fusion drug (an antibody linked a cytotoxic protein payload that, in and of itself, is designed for the localized cancer destruction). The said antibody zones in on specific cancer cells while the cytotoxic protein kills rogue tumors. Interestingly, TPT can be employed as either a promising single drug or in combinations with other immuno-oncology agents such as checkpoint inhibitors.

Interestingly, Eleven commenced a trial at the US National Cancer Institute (NCI) back on Sept. 2017 to study the prospects of Vicinium – a protein coupled with an antibody to attack EpCAM positive tumor – in combinations with AstraZeneca (NYSE:AZN)s immune checkpoint inhibitor, Imfinzi for high-grade non-muscle invasive bladder cancer (NMIBC). If the data turns out robust as we anticipated, AstraZeneca is likely to acquire the company. That aside, the VISTA trial investigating Vicinium as a monotherapy for NMIBC will report the topline results in several months. There is a favorable chance that this clinical binary to post positive outcomes to catapult the shares over 80%. Be that as it may, there is a risk that the shares can tumble by similar the magnitude.

Bioscience Catalysts

On April 26, 2018, Achaogen (NASDAQ:AKAO) announced that it has entered into an award agreement with CARB-X. Under the terms, Achaogen to receive the initial $2.4M (and potentially $9.6M more, pending on certain milestones achievement). As a company featured in our Specialty Report, Achaogen seeks to develop and commercialize the next-generation antibiotics (to service multi-drug resistant gram-negative infection).

Notably, the aforementioned collaboration to assist the company in innovating a next-generation broad-spectrum aminoglycoside that can circumvent the highly resistant gram-negative bugs such as Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. It is interesting to realize that in 2017, the World Health Organization recognized multi-drug resistant P. aeruginosa, A. baumannii and various Enterobacteriaceae as priority 1 critical pathogens that pose the greatest threat to human health.

Final Remarks

In all, the market finished the week on a positive tune. Notable companies either rode this rays of optimism or made our featured list today include Eleven Biotherapeutics and Achaogen. Its highly likely that Eleven bulls will continue to charge ahead of the clinical binary for Vicinium. That aside, the recent CARB-X award is a testament to the quality of Achaogen antibiotics.

Authors Notes: Were honored that you took the time to read our market intelligence. Founded by Dr. Hung Tran, MD, MS, CNPR, (in collaborations with Analyst Vu, and other PhDs), Integrated BioSci Investing (IBI) is delivering stellar returns. To name a few, Nektar, Spectrum, Atara, and Kite procured over 344%, 114%, 200%, and 83% profits, respectively. Our secret sauce is extreme due diligence with expert data analysis. The service features a once-weekly exclusive Alpha-Intelligence article, daily analysis/consulting, and model portfolios. Of note, there is an IBI version of this article that is a higher-level intelligence with extensive details, in which we published in advanced and exclusively for our subscribers. And, we invite you to subscribe to our marketplace now to lock in the current price and save money for the future.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Additional disclosure: I like to inform our readers of Seeking Alpha’s recent policy change, in which the company implemented the paywall (not only to my articles but to all articles that are published over 10-day). This is in place, as the company is, after all, a business. And, the revenues from ads are not adequate to support the high-quality research that the company is providing. If you are a REAL TIME FOLLOWER, you will be notified immediately of our new research for you to continue to benefit from our due diligence. You can also gain access to all of my old articles and much more by taking the 2-week FREE trial of my marketplace, Integrated BioSci Investing.

Editor’s Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.